Esophageal cancers missed at upper endoscopy in Central Norway 2004 to 2021 - A population-based study.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
21 Aug 2024
Historique:
received: 02 10 2023
accepted: 13 08 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 21 8 2024
Statut: epublish

Résumé

The incidence of esophageal cancers is increasing in many Western countries and the rate of missed esophageal cancers (MEC) at upper endoscopy is of concern. We aimed to calculate the MEC rate and identify factors associated with MEC. This was a retrospective population-based cohort study including 613 patients diagnosed with esophageal cancer in Central Norway 2004-2021. MEC was defined as esophageal cancer diagnosed 6-36 months after a non-diagnostic upper endoscopy. Patient characteristics, tumor localization, histological type and cTNM stage were recorded. Symptoms, endoscopic findings, use of sedation and endoscopists experience at the endoscopy prior to esophageal cancer diagnosis and at the time of diagnosis were recorded. The association between these factors and MEC was assessed. Forty-nine (8.0%) of 613 cancers were MEC. There was a significant increase in annual numbers of esophageal cancer (p < 0.001) as well as of MEC (p = 0.009), but MEC rate did not change significantly (p = 0.382). The median time from prior upper endoscopy to MEC diagnosis was 22.9 (12.1-28.6) months. MEC patients were older and were diagnosed with disease with a lower cTNM stage and cT category than non-missed cancers, whereas tumor localization and histological type were similar between the groups. The use of sedation or endoscopist experience did not differ between the endoscopy prior to esophageal cancer diagnosis and at the time of diagnosis. High proportions of MEC patients had Barrett's esophagus (n = 25, 51.0%), hiatus hernia (n = 26, 53.1%), esophagitis (n = 10, 20.4%) or ulceration (n = 4, 8.2%). Significant proportions of MECs were diagnosed after inappropriate follow-up of endoscopic Barrett's esophagus, histological dysplasia or ulcerations. The annual number of MEC increased during the study period, while the MEC rate remained unchanged. Endoscopic findings related to gastroesophageal reflux disease such as esophagitis and Barrett's esophagus were identified in a high proportion of patients with subsequent MECs. Cautious follow-up of these patients could potentially reduce MEC-rate.

Identifiants

pubmed: 39169296
doi: 10.1186/s12876-024-03371-z
pii: 10.1186/s12876-024-03371-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

279

Informations de copyright

© 2024. The Author(s).

Références

WHO -. International Agency for Research on Cancer. Cancer fact sheet. 2020.
Short MW, Burgers KG, Fry VT. Esophageal Cancer. Am Fam Physician. 2017;95(1):22–8.
pubmed: 28075104
Cancer in. Norway 2021 - Cancer incidence, mortality, survival and prevalence in Norway. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2020/cin-2020.pdf
Kamangar F, Nasrollahzadeh D, Safiri S, Sepanlou SG, Fitzmaurice C, Ikuta KS, Bisignano C, Islami F, Roshandel G, Lim SS. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):582–97.
doi: 10.1016/S2468-1253(20)30007-8
Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721–32.
pubmed: 11562112 doi: 10.1023/A:1011290704728
Annual report. 2016: results and improvement measures from the national quality register for esophageal- and ventricular cancer. https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_spiseror-og-magesekkreft.pdf
Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210–5.
pubmed: 27986415 doi: 10.1016/j.asjsur.2016.10.005
Vendrely V, Launay V, Najah H, Smith D, Collet D, Gronnier C. Prognostic factors in esophageal cancer treated with curative intent. Dig Liver Dis. 2018;50(10):991–6.
pubmed: 30166221 doi: 10.1016/j.dld.2018.08.002
Rodríguez de Santiago E, Hernanz N, Marcos-Prieto HM, De-Jorge-Turrión M, Barreiro-Alonso E, Rodríguez-Escaja C, Jiménez-Jurado A, Sierra-Morales M, Pérez-Valle I, Machado-Volpato N, et al. Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: a multicentric cohort study. United Eur Gastroenterol J. 2019;7(2):189–98.
doi: 10.1177/2050640618811477
Shinozaki S, Osawa H, Hayashi Y, Lefor AK, Yamamoto H. Linked color imaging for the detection of early gastrointestinal neoplasms. Therapeutic Adv Gastroenterol. 2019;12:1756284819885246.
doi: 10.1177/1756284819885246
van Putten M, Johnston BT, Murray LJ, Gavin AT, McManus DT, Bhat S, Turkington RC, Coleman HG. Missed’oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus patients: a large population-based study. United Eur Gastroenterol J. 2018;6(4):519–28.
doi: 10.1177/2050640617737466
Chadwick G, Groene O, Hoare J, Hardwick RH, Riley S, Crosby TD, Hanna GB, Cromwell DA. A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy. Endoscopy. 2014;46(7):553–60.
pubmed: 24971624 doi: 10.1055/s-0034-1365646
Bloomfeld RS, Bridgers DI, Pineau BC. Sensitivity of upper endoscopy in diagnosing esophageal cancer. Dysphagia. 2005;20:278–82.
pubmed: 16633872 doi: 10.1007/s00455-005-0025-x
Wang YR, Loftus EV Jr, Judge TA, Peikin SR. Rate and predictors of interval esophageal and gastric cancers after esophagogastroduodenoscopy in the United States. Digestion. 2016;94(3):176–80.
pubmed: 27871069 doi: 10.1159/000452794
Brierly JG, Wittekind MK. C.: International Union Against Cancer (UICC) TNM classification of malignant tumors. 8th ed. Oxford, UK: Wiley-Blackwell; 2016.
Rubenstein JH, Waljee AK, Dwamena B, Bergman J, Vieth M, Wani S. Yield of higher-grade neoplasia in Barrett’s esophagus with low-grade dysplasia is double in the first year following diagnosis. Clin Gastroenterol Hepatol. 2018;16(9):1529–30.
pubmed: 29307847 pmcid: 6030504 doi: 10.1016/j.cgh.2018.01.002
Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2016;150(3):599–607. e597.
pubmed: 26619962 doi: 10.1053/j.gastro.2015.11.040
Cheung D, Menon S, Hoare J, Dhar A, Trudgill N. Factors associated with upper gastrointestinal cancer occurrence after endoscopy that did not diagnose cancer. Dig Dis Sci. 2016;61:2674–84.
pubmed: 27129486 doi: 10.1007/s10620-016-4176-4
Guanrei Y, Songliang Q, He H, Guizen F. Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the people’s Republic of China. Endoscopy. 1988;20(03):95–8.
pubmed: 3383810 doi: 10.1055/s-2007-1018145
Wang G, Wei W, Hao C, Zhang J, Lü N. Natural progression of early esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 2010;32(8):600–2.
pubmed: 21122412
Nagaya TN, Miyhara Y, Nakamura R, Iguchi M, Kodama Y, Banno Y, Maeda K, Ando O, Itoh T, Ohmiya A, Hirooka N, Goto Y. Natural history of the esophageal carcinoma -prospective and retrospective study by Endoscopy. Gastrointest Endosc. 2008;67(5):AB183.
doi: 10.1016/j.gie.2008.03.445
Wang JW, Guan CT, Wang LL, Chang LY, Hao CQ, Li BY, Lu N, Wei WQ. Natural history analysis of 101 severe dysplasia and esophageal carcinoma cases by Endoscopy. Gastroenterol Res Pract 2017, 2017:9612854.
Rodriguez de Santiago E, Hernanz N, Marcos-Prieto HM, De-Jorge-Turrion MA, Barreiro-Alonso E, Rodriguez-Escaja C, Jimenez-Jurado A, Sierra-Morales M, Perez-Valle I, Machado-Volpato N, et al. Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: a multicentric cohort study. United Eur Gastroenterol J. 2019;7(2):189–98.
doi: 10.1177/2050640618811477
Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling–Sternevald E, Vieth M, Stolte M, Talley NJ, Agréus L. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–31.
pubmed: 16344051 doi: 10.1053/j.gastro.2005.08.053
Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627–36.
pubmed: 23942681 doi: 10.1001/jama.2013.226450
Andrici J, Tio M, Cox MR, Eslick GD. Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol. 2013;28(3):415–31.
pubmed: 22694245 doi: 10.1111/j.1440-1746.2012.07199.x
Qumseya BJ, Wani S, Gendy S, Harnke B, Bergman JJ, Wolfsen H. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Official J Am Coll Gastroenterology| ACG. 2017;112(6):849–65.
doi: 10.1038/ajg.2017.70
Fitzgerald RC, Di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.
pubmed: 24165758 doi: 10.1136/gutjnl-2013-305372
Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, Agrawal D, Buxbaum JL, Fishman DS, Gurudu SR. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90(3):335–59. e332.
pubmed: 31439127 doi: 10.1016/j.gie.2019.05.012
Higuchi D, Sugawa C, Shah SH, Tokioka S, Lucas CE. Etiology, treatment, and outcome of esophageal ulcers: a 10-year experience in an urban emergency hospital. J Gastrointest Surg. 2003;7(7):836–42.
pubmed: 14592655 doi: 10.1007/s11605-003-0027-7
Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft–Wheaton G. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143(2):336–46.
pubmed: 22537613 doi: 10.1053/j.gastro.2012.04.032
Nachiappan A, Ragunath K, Card T, Kaye P. Diagnosing dysplasia in Barrett’s oesophagus still requires Seattle protocol biopsy in the era of modern video endoscopy: results from a tertiary centre Barrett’s dysplasia database. Scand J Gastroenterol. 2020;55(1):9–13.
pubmed: 31880176 doi: 10.1080/00365521.2019.1706762
Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–57.
pubmed: 21680910 pmcid: 3632011 doi: 10.1093/jnci/djr203
Tai FWD, Wray N, Sidhu R, Hopper A, McAlindon M. Factors associated with oesophagogastric cancers missed by gastroscopy: a case–control study. Frontline Gastroenterol. 2020;11(3):194–201.
pubmed: 32419910 doi: 10.1136/flgastro-2019-101217
Singh S, Singh PP, Murad MH, Singh H, Samadder JN. Prevalence, risk factors, and outcomes of interval colorectal cancers: a systematic review and meta-analysis. Official J Am Coll Gastroenterology| ACG. 2014;109(9):1375–89.
doi: 10.1038/ajg.2014.171
Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007;132(1):96–102.
pubmed: 17241863 doi: 10.1053/j.gastro.2006.10.027
Singh H, Nugent Z, Demers AA, Bernstein CN. Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Official J Am Coll Gastroenterology| ACG. 2010;105(12):2588–96.
doi: 10.1038/ajg.2010.390
Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology. 2011;140(1):65–72.
pubmed: 20854818 doi: 10.1053/j.gastro.2010.09.006
Cooper GS, Xu F, Barnholtz Sloan JS, Schluchter MD, Koroukian SM. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer. 2012;118(12):3044–52.
pubmed: 21989586 doi: 10.1002/cncr.26602
Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, Pech O, Ragunath K, Weusten B, Familiari P. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy quality improvement initiative. United Eur Gastroenterol J. 2016;4(5):629–56.
doi: 10.1177/2050640616664843
Beg S, Ragunath K, Wyman A, Banks M, Trudgill N, Pritchard MD, Riley S, Anderson J, Griffiths H, Bhandari P. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017;66(11):1886–99.
pubmed: 28821598 doi: 10.1136/gutjnl-2017-314109
Ebi M, Shimura T, Yamada T, Mizushima T, Itoh K, Tsukamoto H, Tsuchida K, Hirata Y, Murakami K, Kanie H, et al. Multicenter, prospective trial of white-light imaging alone versus white-light imaging followed by magnifying endoscopy with narrow-band imaging for the real-time imaging and diagnosis of invasion depth in superficial esophageal squamous cell carcinoma. Gastrointest Endosc. 2015;81(6):1355–e13611352.
pubmed: 25683023 doi: 10.1016/j.gie.2014.11.015
Kamran U, Abbasi A, Umar N, Tahir I, Brookes MJ, Rutter M, McCord M, Adderley NJ, Dretzke J, Trudgill N. Umbrella systematic review of potential quality indicators for the detection of dysplasia and cancer at upper gastrointestinal endoscopy. Endosc Int Open. 2023;11(9):E835–48.
pubmed: 37719799 pmcid: 10504040 doi: 10.1055/a-2117-8621
Raftopoulos SC, Segarajasingam DS, Burke V, Ee HC, Yusoff IF. A cohort study of missed and new cancers after esophagogastroduodenoscopy. Official J Am Coll Gastroenterology| ACG. 2010;105(6):1292–7.
doi: 10.1038/ajg.2009.736
Ladas SD, Satake Y, Mostafa I, Morse J. Sedation practices for gastrointestinal endoscopy in Europe, North America, Asia, Africa and Australia. Digestion. 2010;82(2):74–6.
pubmed: 20407247 doi: 10.1159/000285248

Auteurs

Synne Straum (S)

Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU, Trondheim, Norway.

Karoline Wollan (K)

Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU, Trondheim, Norway.

Lars Cato Rekstad (LC)

Department of Gastrointestinal Surgery, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.

Reidar Fossmark (R)

Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU, Trondheim, Norway. reidar.fossmark@ntnu.no.
Department of Gastroenterology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. reidar.fossmark@ntnu.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH